Our mission is to detect cancer earlier and to increase survival rates
See our crowdfunding video
A future standard clinical tool
Liquid Biopsies in Cancer
While biopsies of tumors are currently considered the gold standard practice, they are invasive procedures that typically require surgery or needles. Often there’s insufficient tissue to analyze, or a tumor is precariously located, making a biopsy unsafe. Tissue biopsies can detect the presence of cancer, but they are inadequate for monitoring people for relapse or identifying the need for alternative treatments.
Scientists have during the last decade developed liquid biopsies - tests that search for evidence of cancer in a person’s bloodstream. The ability to isolate and study circulating tumor cells (CTC) as well as circulating tumor DNA (ctDNA), extracellular vesicles (EVs) and circulating tumor antigens (CTA) in blood and other body fluids is expected to become a critical factor in future diagnostic, prognostic and personalized therapeutic cancer programs. Which holds for the major solid tumor cancers as well as for leukemia.
Circulating tumor DNA (ctDNA) is found in the bloodstream and refers to DNA that is fragmented from the cancerous cells and tumors.
Extracellular vesicles (EVs) are lipid bilayer-delimited particles that are naturally released from almost all types of cell and, unlike a cell, cannot replicate.
Circulating tumor cells (CTC) are cells that have shed into the vasculature or lymphatics from a primary tumor and is carried around the body in the blood circulation.
Circulating tumor antigen (CTA) are multifunctional protein groups with specific expression patterns in normal embryonic and adult cells and various types of cancer cells.
The increasing demand for preventative and personalized medicine has in the past years pushed the value and use of liquid biopsies in oncology. Still, currently, there is no system in the market that allows identification , capture, isolation, and cultivation of all cancer biomarkers: All in one product.
From my clinical experience , I strongly believe that a single product that allows identification , capture, isolation and cultivation of CTCs along with other cancer biomarkers (ctDNA, exosomes and proteins) has the potential to disrupt the current precision and personalised cancer medicine workflow, bringing significant benefits for cancer patients.
Jonas Einarson
CEO, Radiumhospitalets Forskningsstiftelse
All-In-One Liquid Biopsy system
Our Solution
GreinDX is developing a first of its kind, proprietary, comprehensive bench-top system that can capture and study CTCs, ctDNA, EVs and CTA from a single blood sample or from other body fluids
Our core technology is a porous surface of crystalline material of silicon- organic framework characterized by ordered structure, uniform porosity, and high surface area that are the ideal attributes for fluid separation, sorting its constituents and storing them.
The organic building blocks are our short proprietary peptides tailored towards a specific biomarker, with ends that allow controlled linking with other peptides or the silicon surface. The modular assemblage allows precise patterning that ensures structural and functional control over the sorting process.
The ctDNA, EVs, and other cancer-specific macromolecules are captured by dividing the same blood sample into millions of nano-sized droplets that are filtered through and probed individually with affinity peptides allowing their further investigation by PCR or biochemical analysis.
Our bench-top system will provide soluble factors via a microfluidic system, live cell imaging and online electrochemical measurement via a pair of well- specific electrodes, allowing pharmaceutical assaying of the captured cells.
Our bodies are made up of more than 30 trillion cells. Cancer cells are cells that divide relentlessly, forming solid tumors or flooding the blood with abnormal cells.
It can take up to 20 years from a damage cell to divide and grow and form a tumor large enough to cause symptoms.
It is estimated that if cancer is found at an earlier stage, there is a 3−10 times higher survival rate.
About Us
GreinDX AS was incorporated in December 2018 by a multidisciplinary group of experts from the USA, Israel, Norway and Canada that have joined forces to develop a novel liquid biopsy platform. Together with our partners, we have created a unique consortium with extensive experience and knowledge from global innovative organizations.
Our mission is to detect cancer earlier, and to increase survival rates.
The People
Ove Solesvik MSc
CEO and Co-Founder
Dr. Amir Lichtenstein
CTO and Co-Founder
Kristina H. Bollingmo MSc
CCO and Co-Founder
Aaron Kapelus BSc
Project Manager and Quality Control
Christian Fredrik Stray
Advisor and Board Member
Ane S. Oppedal MSc
Consultant
Dr. Jean-Marc Billod
Bioinformatics Consultant
Dr. Chai Ezerzer
Symthera Canada Consultant
Dr. Warren Flood
Microbiology Consultant
For both preventive and precision medicine, we are seeing increasing interest in the use of liquid biopsies in the oncology space. However, there is, to our knowledge, no system currently available that allows identification, capture, isolation, and cultivating of circulating tumor cells (CTC) and other key cancer biomarkers in a single product. We are intrigued by the comprehensive approach that GreinDX is taking to address this challenge and are enthusiastic about the prospect of this “all in one” solution.
Mark J. Powers, Ph.D
Vice President R&D
Cell Biology, Cell Culture and Cell Therapy, Thermo Fisher Scientific
Our Partners
Prof. Vessela Kristensen
Department of Medical Genetics & Development
Oslo University Hospital
Dr. Geir Uri Jensen
Senior Scientist
SINTEF, MiNaLab
Petter Arlhed
Advisor Product
CEO & Founder Yallow
We want to hear from you!
Our development of a new diagnostic platform will be both demanding and challenging, but we are driven and fueled by our team’s expertise, curiosity and optimism. As Einstein once said,“Concern for man and his fate must always form the chief interest of all technical endeavors.” We hope you join us on our journey of making early detection of cancer available for everyone.